dasatinib

Treatment type:

Oral therapies

Code name:

BMS-354825

Commercial name:

Sprycel

Treatment line:

First line
Second line
Third line
Fourth line
Fifth line

Generation:

Second

Dasatinib is a highly potent dual Src/Abl inhibitor. It inhibits most mutations with the exception of the T315i mutation. The results of CCyR and MMR are similar to nilotinib. When this inhibitor was employed as first-line treatment, the responses were deeper, faster and superior to imatinib. The major side effects of this TKI inhibitor are thrombocytopenia, pleural effusion and more rarely, pulmonary complications.

Status:

England

Available in England and the devolved NHS administrations as a routine treatment for its licensed indications

Scotland

Available as a routine treatment for its licensed indications

Wales

Available as a routine treatment for its licensed indications

Northern Ireland

Available as a routine treatment for its licensed indications

type: Clinical trial